CN105050613A - 降低与心脏衰竭相关的风险和与其相关的因素的方法 - Google Patents

降低与心脏衰竭相关的风险和与其相关的因素的方法 Download PDF

Info

Publication number
CN105050613A
CN105050613A CN201380067076.XA CN201380067076A CN105050613A CN 105050613 A CN105050613 A CN 105050613A CN 201380067076 A CN201380067076 A CN 201380067076A CN 105050613 A CN105050613 A CN 105050613A
Authority
CN
China
Prior art keywords
subject
heart failure
agents
peptide
drugs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380067076.XA
Other languages
English (en)
Chinese (zh)
Inventor
D·特拉维斯·威尔逊
哈尼·N·萨巴赫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stealth Peptides International Inc
Henry Ford Health System
Original Assignee
Stealth Peptides International Inc
Henry Ford Health System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stealth Peptides International Inc, Henry Ford Health System filed Critical Stealth Peptides International Inc
Priority to CN201910384895.6A priority Critical patent/CN110193077A/zh
Publication of CN105050613A publication Critical patent/CN105050613A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Emergency Medicine (AREA)
CN201380067076.XA 2012-10-22 2013-10-22 降低与心脏衰竭相关的风险和与其相关的因素的方法 Pending CN105050613A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910384895.6A CN110193077A (zh) 2012-10-22 2013-10-22 降低与心脏衰竭相关的风险和与其相关的因素的方法

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201261716867P 2012-10-22 2012-10-22
US61/716,867 2012-10-22
US201361822752P 2013-05-13 2013-05-13
US61/822,752 2013-05-13
US201361839750P 2013-06-26 2013-06-26
US201361839743P 2013-06-26 2013-06-26
US61/839,750 2013-06-26
US61/839,743 2013-06-26
PCT/US2013/066228 WO2014066419A2 (en) 2012-10-22 2013-10-22 Methods for reducing risks associated with heart failure and factors associated therewith

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201910384895.6A Division CN110193077A (zh) 2012-10-22 2013-10-22 降低与心脏衰竭相关的风险和与其相关的因素的方法

Publications (1)

Publication Number Publication Date
CN105050613A true CN105050613A (zh) 2015-11-11

Family

ID=50545459

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380067076.XA Pending CN105050613A (zh) 2012-10-22 2013-10-22 降低与心脏衰竭相关的风险和与其相关的因素的方法
CN201910384895.6A Pending CN110193077A (zh) 2012-10-22 2013-10-22 降低与心脏衰竭相关的风险和与其相关的因素的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201910384895.6A Pending CN110193077A (zh) 2012-10-22 2013-10-22 降低与心脏衰竭相关的风险和与其相关的因素的方法

Country Status (13)

Country Link
US (4) US20150246092A1 (https=)
EP (5) EP4005582A1 (https=)
JP (3) JP2016503397A (https=)
KR (1) KR20160009008A (https=)
CN (2) CN105050613A (https=)
AU (2) AU2013334788A1 (https=)
BR (1) BR112015009072A2 (https=)
CA (1) CA2889155A1 (https=)
ES (1) ES3058737T3 (https=)
MX (1) MX2015005102A (https=)
NI (1) NI201500057A (https=)
PE (1) PE20151434A1 (https=)
WO (1) WO2014066419A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109414472A (zh) * 2016-06-24 2019-03-01 南加利福尼亚大学 Mentsh类似物作为用于糖尿病、肥胖及其相关疾病和并发症的治疗剂

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2755134T3 (es) 2013-03-01 2020-04-21 Stealth Biotherapeutics Corp Métodos para el tratamiento de enfermedad mitocondrial
US9687519B2 (en) 2013-03-01 2017-06-27 Stealth Biotherapeutics Corp Methods and compositions for the prevention or treatment of barth syndrome
CA2916977A1 (en) 2013-06-26 2014-12-31 Stealth Biotherapeutics Corp Methods and compositions for detecting and diagnosing diseases and conditions
WO2017180535A1 (en) 2016-04-11 2017-10-19 Carnot, Llc Chiral peptides
KR20200012823A (ko) * 2017-02-01 2020-02-05 예일 유니버시티 이뇨제 내성의 치료
EP3735421A4 (en) 2018-01-05 2021-09-22 Corvidia Therapeutics, Inc. METHOD OF TREATMENT OF IL-6 MEDIATED INFLAMMATION WITHOUT IMMUNSUPPRESSION
KR102546547B1 (ko) 2018-01-11 2023-06-22 삼성전자주식회사 보행 보조 방법 및 장치
KR20220052561A (ko) 2020-10-21 2022-04-28 장영진 어류 가공물 및/또는 콩 가공물을 유효성분으로 포함하는 심부전의 예방 또는 치료용 약학 조성물
CN120329388B (zh) * 2025-04-30 2025-09-26 中日友好医院(中日友好临床医学研究所) 一种双靶点多肽及其在心衰治疗中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004070054A3 (en) * 2003-02-04 2005-04-14 Cornell Res Foundation Inc Methods for preventing mitochondrial permeability transition
WO2011082324A1 (en) * 2009-12-31 2011-07-07 Stealth Peptides International, Inc. Methods for the prevention or treatment of vessel occlusion injury

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
WO2004009776A2 (en) * 2002-07-19 2004-01-29 Abbott Biotechnology Ltd. TREATMENT OF TNFα RELATED DISORDERS
EP1890153A1 (en) * 2006-08-16 2008-02-20 F. Hoffman-la Roche AG Cardiac troponin as an indicator of advanced coronary artery disease
EP1890154B1 (en) * 2006-08-16 2012-07-04 F. Hoffmann-La Roche AG Cardiac troponin as an indicator of advanced coronary artery disease
US20080318909A1 (en) * 2007-06-14 2008-12-25 Sparagna Genevieve C Use Of Linoleic Compounds Against Heart Failure
EP3741381B1 (en) * 2008-02-26 2024-04-24 Cornell University A peptide for use for prevention and treatment of acute renal injury
WO2011019809A1 (en) * 2009-08-12 2011-02-17 Cornell University Methods for preventing or treating metabolic syndrome
WO2011044044A1 (en) * 2009-10-05 2011-04-14 Cornell University Methods for the prevention or treatment of heart failure
CN102740888B (zh) * 2009-11-24 2016-10-12 奥尔德生物制药公司 Il-6抗体及其用途
EP3266462A1 (en) * 2009-12-31 2018-01-10 Stealth Peptides International, Inc. Methods for performing a coronary artery bypass graft procedure
JP2013521231A (ja) * 2010-02-26 2013-06-10 ユニバーシティ オブ フロリダ リサーチ ファウンデーション インコーポレイテッド ミトコンドリア標的化抗酸化剤は機械的人工呼吸誘発性横隔膜機能障害および骨格筋萎縮を防止する
EP3375449A1 (en) * 2010-03-15 2018-09-19 Stealth Peptides International, Inc. Combination therapies using cyclosporine and aromatic cationic peptides
JP2015529655A (ja) * 2012-08-02 2015-10-08 ステルス ペプチドズ インターナショナル インコーポレイテッド アテローム性硬化症の処置方法
JP2016506391A (ja) * 2012-12-06 2016-03-03 ステルス ペプチドズ インターナショナル インコーポレイテッド ペプチド治療薬およびその使用方法
WO2014210062A1 (en) * 2013-06-26 2014-12-31 Stealth Peptides International, Inc. Methods for the regulation of matrix metalloproteinase expression
CA2916977A1 (en) * 2013-06-26 2014-12-31 Stealth Biotherapeutics Corp Methods and compositions for detecting and diagnosing diseases and conditions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004070054A3 (en) * 2003-02-04 2005-04-14 Cornell Res Foundation Inc Methods for preventing mitochondrial permeability transition
WO2011082324A1 (en) * 2009-12-31 2011-07-07 Stealth Peptides International, Inc. Methods for the prevention or treatment of vessel occlusion injury

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
姚陈一: "冠状动脉旁路移植术后低氧血症相关危险因素分析", 《国际心血管病杂志》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109414472A (zh) * 2016-06-24 2019-03-01 南加利福尼亚大学 Mentsh类似物作为用于糖尿病、肥胖及其相关疾病和并发症的治疗剂

Also Published As

Publication number Publication date
NI201500057A (es) 2015-07-16
ES3058737T3 (en) 2026-03-12
EP2908839A4 (en) 2016-06-15
JP2018109012A (ja) 2018-07-12
EP2908839A2 (en) 2015-08-26
EP4005582A1 (en) 2022-06-01
BR112015009072A2 (pt) 2017-07-04
JP2019194193A (ja) 2019-11-07
EP4397314A1 (en) 2024-07-10
EP4397314B1 (en) 2025-12-03
EP3586862A1 (en) 2020-01-01
AU2013334788A1 (en) 2015-06-04
US20230190859A1 (en) 2023-06-22
KR20160009008A (ko) 2016-01-25
EP4711005A3 (en) 2026-04-22
MX2015005102A (es) 2016-02-09
HK1213799A1 (en) 2016-07-15
AU2018206766A1 (en) 2018-08-09
WO2014066419A2 (en) 2014-05-01
US20250255929A1 (en) 2025-08-14
WO2014066419A3 (en) 2014-06-12
EP4711005A2 (en) 2026-03-18
CA2889155A1 (en) 2014-05-01
EP3586862B1 (en) 2021-12-08
US20200360462A1 (en) 2020-11-19
JP2016503397A (ja) 2016-02-04
US20150246092A1 (en) 2015-09-03
CN110193077A (zh) 2019-09-03
PE20151434A1 (es) 2015-10-16
EP2908839B1 (en) 2019-08-21

Similar Documents

Publication Publication Date Title
US20250255929A1 (en) Methods for reducing risks associated with heart failure and factors associated therewith
JP7072692B2 (ja) バース症候群の予防または治療のための方法及び組成物
US11312993B2 (en) Methods and compositions for detecting and diagnosing diseases and conditions
US20250319152A1 (en) Methods for the prevention or treatment of left ventricle remodeling
HK40115529A (en) Treatment of left ventricular remodeling
HK40115529B (en) Treatment of left ventricular remodeling
HK1213799B (en) Methods for reducing risks associated with heart failure and factors associated therewith
HK1222794B (en) Methods for the prevention or treatment of left ventricle remodeling

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20151111

RJ01 Rejection of invention patent application after publication